

March 25-27 2025 | Boston, MA
www.biophysics-drugdiscovery.com

REGISTER BY
MARCH 24 TO
SAVE \$100



2nd Annual

Biophysics for Drug Discovery Summit

Advances in Biophysics Technologies & Applications to Measure Molecular Interactions

Harnessing Biophysical Techniques Across Modalities & Targets from Hit ID & Characterization to Lead Selection & Optimization to Transform the Efficiency of the Early Drug Discovery Process

Expert Speakers Include:



Taiana Maia de Oliveira
Director of Biophysics
UK
AstraZeneca



Alexey Rak
Head of Biostructure
& Biophysics
Sanofi



Matthew Calabrese
Senior Director &
Head of Structural &
Molecular Sciences
Pfizer



Krishna Padmanabha Das
Senior Scientist, Drug
Discovery
St Jude Children's
Research Hospital



Debaleena Basu
Senior Scientist
Amgen



Jesper Marino
Principal Scientist,
Automation
Novo Nordisk

2025 Partners:



+1 617 455 4188 @ info@hansonwade.com

https://biophysics-drugdiscovery.com/



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the 2nd Biophysics for Drug Discovery Summit

2nd Annual Biophysics for Drug Discovery Summit

March 25-27 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

In today's complex drug development landscape, understanding the intricacies at a molecular and target engagement level using biophysical tools to then advance a molecule into further drug development is more paramount than ever. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery peers and delve into the application of biophysical techniques including SPR, NMR, Thermal shift assays, mass spec, and the new technologies across modalities and targets to inform efficient drug discovery.

Hosting the unmissable and unique opportunity to explore the latest advancements and challenges in harnessing biophysical techniques to accelerate drugs discovery from hits to leads, this two day event brings together the biophysics leads from biopharma to discuss:

- Employing cutting edge techniques to characterise drug candidates and optimise their properties
- Utilising biophysics to identify and prioritise promising drug candidates and de-risk early-stage development
- Delving into case studies from small molecules and biologics and peptides to take cross-learnings and optimise your biophysical strategies
- Explore the application of biophysics techniques on new modalities including protein degradation, molecular glues, PROTACs, and more

Unlock the future of therapeutics through biophysics and keep up to date as field evolves into new technologies and applications, this meeting will provide you with thought-provoking insights on biophysics applications to take away to your wider drug discovery teams. Join the Biophysics for Drug Discovery Summit in March 2025 and build meaningful connections with 70+ biophysicists and drug discovery experts and move the field forward with unique insights and deep-dive conversations.

5 Key Benefits of Attending:

What Past Attendees Had to Say:

“The amalgamation of different approaches to tackle some of the most challenging biophysics problems was a standout for me. 1-1 interactions with different scientists and leaders from different companies was a great opportunity to exchange ideas”

**Associate Director,
Accent Therapeutics**

“Great discussion and real world worked examples to illustrate the content made the focus better”

**Senior Principal Scientist,
Vertex Pharmaceuticals**



Gain insights from **Novartis** and **Foghorn Therapeutics** into emerging modalities, like protein degraders and strategies, including fragment-based drug design, and their potential to attack undruggable targets.



Apply AI-driven virtual screening and automation to accelerate drug discovery processes and improve hit-to-lead optimization with **Novo-Nordisk**, **AI Protein** and the **Institute of Cancer Research**.



Review the use of technologies and modalities with big pharma experts, including **AstraZeneca**, **Sanofi** and **Pfizer** from their studies, strategies and challenges in leveraging biophysics to accelerate drug development.



Explore the latest developments in in-cell biophysics and single-particle tracking, and understand how these techniques can provide critical insights into drug mechanisms of action with **UCB**, **Roche** and **NYU**.



Apply insights from successful hit-to-lead case studies from **Stablix** and **Kymera** that showcase the power of biophysics in driving drug discovery projects from early-stage research to clinical trials.

Your 20+ Expert Speakers

Biophysics for Drug
Discovery Summit

March 25-27 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Alexey Rak
Head of Biostructure &
Biophysics
Sanofi



Andreas Frutiger
Vice President R&D
lino Biotech AG



Arne Rufer
Expert Scientist & Science
& Technology Lead, Lead
Discovery
Roche



Ben Levin
Principal Scientist
Stablix Inc.



Debaleena Basu
Senior Scientist
Amgen Inc.



Dipti Sadalge
Principal Scientist
**Foghorn Therapeutics
Inc.**



Goran Malojcic
Lab Head, Biochemistry &
Biophysics
Novartis AG



Griffin Schroeder
Scientist II
Arrakis Therapeutics



James Bowman
Director of Protein
Engineering
AI Proteins



Janice Villali
Head of Biophysics
Relay Therapeutics



Jesper Marino
Principal Scientist,
Automation
Novo Nordisk



**Krishna Padmanabha
Das**
Senior Scientist, Drug
Discovery
**St Jude Children's
Research Hospital**



Laura Caccianini
Post doctoral researcher
**Massachusetts Institute
of Technology**



Matthew Calabrese
Senior Director & Head
of Structural & Molecular
Sciences
Pfizer



**Moran Jerabek-
Willemsen**
Head of Hit Identification &
Profiling
**WuXi Apptec/CreLux
GmbH**



Nicolas Bocquet
Director of Protein
Sciences, Structural
Biology, Protein
Biochemistry & Biophysics
ForX Therapeutics




Oscar Huang
Associate Director of
Biophysics
Lyterian Therapeutics



Rob Van Montfort
Group Leader, Hit
Discovery & Structural
Design
**Institute of Cancer
Research**



Taiana Maia de Oliveira
Director of Biophysics UK
AstraZeneca



Tamar Schlick
Professor of Chemistry,
Mathematics & Computer
Science
New York University

▄▄ There was a good mix of topics and expertise during the conferences and the networking was a big plus. The smaller nature of this conference also allowed for more in-depth and candid conversations ▄▄

Senior Scientist, LifeMine Therapeutics

Pre-Conference Workshop

Tuesday, March 25 2025

Biophysics for Drug
Discovery Summit

March 25-27 2025 | Boston, MA

WELCOME

Check-In & Refreshments

12.30

Workshop

1.00

Delving into the Emerging Technological Advancements & Techniques For Characterizing Drugs for a More Holistic Approach to Discovery

Advance Your Drug Discovery with Cutting-Edge Biophysics: This workshop offers a focused exploration of essential biophysical techniques, from SPR and HTS to advanced methods like DELs and MST, and emerging areas like covalent modalities. Learn how to leverage these tools for efficient hit identification, detailed interaction analysis, and optimised lead development. Gain practical insights from expert-led sessions on computational methods, NMR, and single-molecule approaches. Explore real-world applications through in-depth case studies demonstrating biophysics across the drug discovery pipeline. Discover how to apply these strategies across the drug discovery pipeline and accelerate your research.

- **Discovering a Comprehensive Biophysical Toolkit** through a wide range of biophysical techniques, from HTS and FBDD to advanced methods like SPR, ASMS, DELs, nanoDSF, MST, NMR, and single-molecule techniques, showcasing their application across the drug discovery pipeline
- **Investigating Case Studies** using three detailed projects to demonstrate the practical application of biophysics in stabilising unstable proteins, identifying hits against challenging targets, and elucidating mechanisms of action for therapeutic molecules
- **Exploring Structure-Function Relationships** by emphasizes the importance of understanding drug-target interactions, including kinetic parameters, binding affinities, and structural insights, with a focus on how these insights drive lead optimisation
- **Uncovering Innovation and Emerging Modalities** by addressing cutting-edge developments in biophysics, including the use of computational approaches and the growing importance of covalent modalities in drug design

Workshop Leaders



Nicolas Bocquet
Director of
Protein Sciences,
Structural
Biology, Protein
Biochemistry &
Biophysics
**FoRx
Therapeutics**



Debaleena Basu
Senior Scientist
Amgen Inc.



Ben Levin
Principal Scientist
Stablix Inc.

EXPERT SPEAKERS

AGENDA

End of Pre-Conference Workshop Day

4.00

PARTNER WITH US

▀▀ The choice of speakers and the handpicked areas of focus was outstanding. You did a great job picking a topic not usually covered by other conferences ▀▀

Senior Scientist, St Jude Children's Research Hospital

REGISTER YOUR PLACE

Conference Day 1

Wednesday, 26 March 2025



8.00 Check In & Morning Refreshments



Taiana Maia De Oliveira
Director of Biophysics
UK
AstraZeneca

8.50 Chair's Opening Remarks

Harnessing Biophysics to Drive Early Drug Discovery: Exploring Industry Case Studies



Taiana Maia De Oliveira
Director of Biophysics
UK
AstraZeneca

9.00 **Expanding Drug Discovery Insights: Protein dynamics and real world samples**

- Exploring examples of AstraZeneca studies to understand real-world examples of the techniques in action
- Considering the future directions of Biophysics in drug discovery for more efficient drug development



Alexey Rak
Head of Biostructure &
Biophysics
Sanofi

9.30 **Redefining Biophysics for Biologic Therapeutic Discovery**

- Efficient, High-Resolution MOB Characterization: Cost-effective approaches for precise binding characterization, offering atomic resolution insights into biologics' mechanisms of action
- Comparative Analysis of Structural and Biophysical Methods: Evaluation of high-resolution structural biology techniques versus traditional biophysical and biochemical methods for comprehensive epitope and paratope mapping
- Integrating Biophysics in Developability Assessment: Leveraging both innovative and established biophysical techniques to optimize biologic therapeutic development



Matthew Calabrese
Senior Director &
Head of Structural &
Molecular Sciences
Pfizer

10.00 **Advancing Hits-To-Leads with Biophysical Techniques From Pfizer**

- Integrating biophysical techniques into the drug discovery pipeline to accelerate the identification and development of novel therapeutics
- Utilising biophysical techniques to design, identify and develop hits that are more suited to the desired targets for cost and time saving
- Progressing the development in varying modalities to provide more potential for tailored drug development



10.30 **Speed Networking**

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in Biophysics. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers into the applications of biophysical techniques and technologies in drug discovery



11.15 Morning Break

Illuminating Innovative Biophysical Approaches & Promising Strategies for Revitalising Drug Discovery Across Novel Drug Modalities



Dipti Sadalge
Principal Scientist
Foghorn Therapeutics
Inc.

11.30 **Biochemical & Biophysical Characterization of CBP-selective Degraders**

- CBP and EP300 have a bidirectional synthetic lethal relationship
- Selective inhibitors/ degraders of CBP (and EP300) are highly desired as dual inhibition exhibits hematopoietic toxicity
- Insights into biochemical and biophysical ternary complex assays to probe selectivity of CBP degraders

Conference Day 1

Wednesday, 26 March 2025

12.00 Unleashing the Power of Spectral Shift Technology for Ultra-High Throughput Binding Assays



Moran Jerabek-Willemsen
Head of Hit
Identification & Profiling
WuXi Apptec/Crelux GmbH

- High-throughput screening (HTS) is vital in drug discovery, yet traditional methods like biochemical assays and ASMS face potential limitations. We established a spectral shift-based direct binding assay that enhances precision, sensitivity, and efficiency while reducing sample consumption and turnaround time
- This approach has been successfully applied in ultra HTS against targets such as kinase BTK, CDK2, PIK3CA, and transcription factor STAT6
- Additionally, we developed a high-throughput method to determine Kinact/Ki for non-reversible interactions, offering superior sensitivity and throughput compared to traditional orthogonal methods, and showcased its application in characterizing covalent fragment binding to BTK



12.30 Lunch

Novel Drug Modalities: Innovative Biophysical Approaches & Promising Strategies for Revitalising Discovery



Oscar Huang
Associate Director of
Biophysics
Lyterian Therapeutics

1.30 Round Table Discussion: Navigating the Complex Landscape of Novel Drug Modalities: Challenges, Opportunities, & the Role of Biophysics to Inspire Future Development

- Discussing the potential of novel modalities like protein degraders (PROTACs and molecular glues) for expanding drug horizons
- Exploring the unique challenges and opportunities associated with each modality for more informed development
- Highlighting the role of biophysics in characterizing these modalities and understanding their mechanism of action for the sharing of knowledge



Debaleena Basu
Senior Scientist
Amgen Inc.

2.00 In Vivo Biophysics with Focal Molography: Expanding the Capabilities of Label-Free Interaction Analysis Beyond SPR and BLI

- The principle of focal Molography and fundamental differences to SPR and BLI
- High throughput DNA encoded hit validation with focal Molography
- Label-free GPCR characterization in living cells



Andreas Frutiger
VP R&D
lino Biotech AG

2.10 Deconstruction of HTS Hits Into Fragments As A Route To Discover Potent BCL6 Inhibitors & Degraders

- A comprehensive hit id campaign including VS, HTS and FBS combined with integrated orthogonal biophysical approaches (TSA, SPR, LO-NMR) was crucial in the validation of initial BCL6 screening hits
- Deconstruction of the initial HTS hits into smaller fragments improved solubility and facilitated the structure-based drug design to increase potency
- Biophysical validation using orthogonal techniques enabled a high success rate in the determination of protein-ligand crystal structures supporting the discovery of potent BCL6 inhibitors and degraders with anti-proliferative activity in BCL6-dependent cancer cell lines



Rob Van Montfort
Group Leader Hit
Discovery & Structural
Design
Institute of Cancer Research



2.40 Afternoon Break & Poster Session

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in biophysical approaches and research advancements.
To submit a poster, please contact info@hansonwade.com

Conference Day 1

Wednesday, 26 March 2025

Accelerating Drug Discovery Using High-Throughput & Automation Tools to Aid Biophysical Techniques and Enhance Efficiency



Jesper Marino
Principal Scientist,
Automation
Novo Nordisk

3.10 User-Friendly, Automated, Miniaturized Biophysics Assays

- Miniaturizing to support early research projects by doing biophysics with less material
- Improving sustainability by decreasing the use of plastic tips and plates
- Making assays more user-friendly - FAIR workflows with user developed Low-code web applications



Tamar Schlick
Professor of Chemistry,
Mathematics &
Computer Science
New York University

3.40 Biomolecular Modelling & Simulation & The Integration Of Molecular Dynamics With AI Methods

- Leveraging AI-powered molecular dynamics simulations to rapidly identify potential drug candidates
- Designing proteins with desired properties using advanced computational techniques
- Gaining deeper insights into the mechanisms of disease and develop innovative therapeutic strategies



Krishna Padmanabha Das
Senior Scientist Drug
Discovery
St Judes Children's
Hospital

4.10 Tailoring The Experimental Validation Workflow To Leverage Ultra-Large Virtual Screening For Accelerated Discovery Of Therapeutics

- Structure-based virtual screening is evolving to be a key tool in early drug discovery, with increasing interest in screening multi-billion compound libraries
- Integrating biophysical, biochemical, cellular and structural components of the validation workflow, coupled with computational drug design can accelerate hit validation and triaging
- Delve into the unique benefits and challenges of a virtual-screening driven validation and lead optimization workflow



Taiana Maia De Oliveira
Director of Biophysics
UK
AstraZeneca

4.40 Chair's Closing Remarks

4.55 End of Conference Day 1

■ ■ The drug target space that is accessible with biophysical approaches is constantly growing due to innovation in protein science and refinement of biophysical techniques. The Biophysics in Drug Discovery Summit brings together experts from across the industry to exchange on recent advancements in the field. ■ ■

Expert Scientist, Lead Discovery, Roche

Conference Day 2

Thursday, 27 March 2025



8.15 Check In & Morning Refreshments

8.50 Chair's Opening Remarks

Discovering Biophysical Frontiers: The Emerging Techniques & Technologies to Enhance Drug Discovery



James Bowman
Director of Protein
Engineering
AI Proteins

9.00 **Computationally Guided Design & Testing of De Novo Miniproteins**

- Using generative AI we design 45-60 amino acid miniproteins to bind to desired targets
- We developed a high throughput production platform to express, purify and characterize thousands of unique miniprotein sequences
- Data we generate is used to further optimize the computational tools and improve affinity and developability of hits



Arne Rufer
Expert Scientist &
Science & Technology
Lead, Lead Discovery
Roche

9.30 **Tailored Biophysical Methods For Soluble Enzymes & Transmembrane Receptor Targets**

- Introduction to the enzymes and transmembrane receptor targets being studied by Roche
- Complementary structural, direct binding and enzyme kinetics data for elucidation of small molecule mode of action
- Chemical probe approaches facilitating characterization of GPCR-ligand interactions



10.30 Morning Break & Networking

Analysing Case Studies in Biophysical Approaches to Target Selection, Hit Identification, Mechanism Exploration and Hit-To-Lead Studies To Improve Knowledge & Aid Future Drug Discovery



Goran Malojcic
Lab Head,
Biochemistry &
Biophysics
Novartis AG

11.00 **Combined Screening and Optimization Approaches Enable Discovery of Highly Selective Kinase Inhibitors**

- Targeting kinases with specific small molecule inhibitors holds promise for treating diseases with high unmet medical need, but discovering such selective kinase inhibitors remains a major challenge
- Combined insights from biophysical, biochemical, cellular, and modeling studies, as well as structure-based design enabled the discovery of highly selective compounds with a suitable set of properties for a proof-of-concept study
- Unexpectedly, high selectivity was achievable despite the significant conservation of active site residues, suggesting a key role of dynamics and solvent effects in driving inhibitor selectivity



Griffin Schroeder
Scientist II
Arrakis Therapeutics

11.30 **Unlocking RNA as a Small Molecule Target Through Biophysical & Structural Techniques**

- Understand the advantages of targeting RNA in diseases with difficult protein targets
- Discuss a novel and differentiated platform that utilizes biophysical techniques to evaluate small molecule compounds against RNA targets
- Highlight how an integrative structural biology platform accelerates RNA-targeted drug design



12.00 Lunch

Conference Day 2

Thursday, 27 March 2025

1.00 Hit Validation at the Extremes of Protein Size

Take-aways:

- Case study on discovering validated chemical matter for a DNA-binding domain
- Using a combination of experimental and computational techniques to validate fragment starting points and to drive SAR
- Optimized RED-MS method and its application to hit-validation of hits to large protein complexes



Janice Villali
Head of Biophysics
Relay Therapeutics

1.30 Biophysical Insights for Deubiquitinases Chemical Matter

- Introduction to Stablix and Targeted Protein Stabilization (TPS) and hit ID chemical matter
- Characterization of DUB chemical matter
- Expanding horizons for biophysical characterization



Ben Levin
Principal Scientist
Stablix Inc.

2.00 Panel Discussion: Considering the Future Directions of Biophysics in Drug Discovery

- Highlighting cutting-edge, biophysical techniques that are revolutionizing our understanding of biological systems to accelerate drug discovery
- Exploring the future requirements in techniques for advancing current approaches
- Investigating the current challenges and methods for solving them for improved discovery



Taiana Maia De Oliveira
Director of Biophysics UK
AstraZeneca



James Bowman
Director of Protein Engineering
AI Proteins



Matthew Calabrese
Senior Director & Head of
Structural & Molecular Sciences
Pfizer



Taiana Maia De Oliveira
Director of Biophysics
UK
AstraZeneca

3.00 Chair's Closing Remarks

3.15 End of Conference Day 2

▀▀ All things in the universe are governed by a certain set of laws. Understanding those laws and applying them to drug discovery excites me. I look forward to learning more about the inclusion of biophysics in the drug development process ▀▀

Kyle Martin, Senior Scientist, Boehringer Ingelheim



Expertise Partner - WuXi Biology

WuXi Biology provides a full spectrum of biology services and solutions, supporting stand-alone and integrated projects, from target discovery to candidate selection and clinical trials. Our world-class discovery platform is backed by more than 3,000 scientists, offering expertise in all major disease areas and target classes, across all therapeutic modalities. From small molecules, oligonucleotides, and peptides to antibodies, cell, and gene therapies, our state-of-the-art services, fast turnaround times, and quick study launches meet the diverse needs of our clients.

www.wuxibiology.com



Innovation Partner - lino Biotech AG

lino Biotech AG, a Miltenyi Biotec Company, advances drug discovery with its label-free focal Molography platform, enabling real-time, multiplexed biomolecular interaction analysis in complex biological samples like human serum and living cells. By measuring interactions in their native environment, its MACS® Matchmaker system delivers precise kinetic and affinity data, especially for high-throughput DNA-encoded library (DEL) hit validation. From antibody screening to GPCR analysis, we provide high-sensitivity solutions that accelerate therapeutic development with unmatched biological relevance.

www.lino-biotech.com



Expertise Partner - Gator Bio

Gator Bio is a Silicon Valley biotech company with a mission to help biopharma scientists gain research insights faster. We fused engineering and science expertise to create novel analytical technologies that achieve better performance and more convenient solutions at a fraction of the cost of existing products. This is the biolayer interferometry solution you've been waiting for.

www.gatorbio.com



Event Partner - Curia

Curia is a global Contract Development and Manufacturing Organization with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing to make treatments broadly accessible to patients. Our Small Molecules offering spans discovery to commercial manufacturing and fill-finish services, integrating scientific, process, regulatory and analytical capabilities. Curia's scalable technologies and dedicated teams advance your program through drug substance and drug product manufacturing.

www.curiaglobal.com



Exhibition Partner - SAI Life Sciences

Sai Life Sciences is the fastest-growing contract research, development, and manufacturing organisation (CRDMO) among listed Indian peers (in terms of revenue CAGR as well as EBITDA CAGR from FY22 to FY24). As a pure-play, full-service CRDMO, we work with over 280 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes.

Over the past 25 years, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. As of March 2024, we had 2845 employees across our facilities in India, UK, USA and Japan.

www.sailife.com

Your Global Platform to Foster New & Existing Relationships Within the Ever Evolving Biophysics Field

Biophysics is at the forefront of drug discovery, providing critical insights into hit identification, molecular mechanisms and target selection. By understanding the intricate interplay of biological molecules, biophysicists are accelerating the development of novel therapies that are more effective than existing treatments or target harder to treat diseases. With significant investments pouring into early-stage biophysics research, the potential for growth, collaboration and partnerships is huge.



Reach a Key Audience:

Connect with leading decision-making biophysicists who are driving innovation in drug discovery and have the power to make meaningful relationships.



Elevate Brand Visibility:

Enhance your brand's reputation as a leader in drug discovery and showcase your services and expertise.



Advance Drug Discovery:



Generate commercial opportunities and contribute to the future of drug development by supporting cutting-edge research and fostering collaborations.




Showcase Innovation & Leadership:

Sponsor the summit to position your company as a leader in biophysics for drug discovery, showcasing your latest technologies, research, and expertise to a targeted audience.

SENIORITY OF ATTENDEES*



TYPES OF COMPANIES ATTENDING*



Statistics Taken from the inaugural Biophysics for Drug Discovery

INTERESTED IN PARTNERSHIP OPPORTUNITIES?




CONTACT

Hannah Martin
Partnerships Director
Tel: +1 617 455 4188
Email: hannah.martin@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 www.biophysics-drugdiscovery.com/

 Tel: +1 617 455 4188

 Email: info@hansonwade.com



Industry-Leading Insights: Gain valuable knowledge and perspectives from top experts at Pfizer, AstraZeneca, Sanofi, Foghorn Therapeutics, AI Protein, and MIT to advance your drug discovery projects.



Cutting-Edge Technology: Discover the latest advancements in biophysics technologies, including in-cell biophysics, single molecule tracking, and AI, to address challenges like undruggable targets and translational data acquisition.



Diverse Modalities: Explore the application of biophysics to a wide range of therapeutic modalities, from small molecules to large complexes, to improve current treatments.



Networking Opportunities: Connect with decision-making biophysicists to share knowledge, forge collaborations, and expand your network.



Present a Poster: Showcase your research to the Biophysics community.

| Drug Developer Pricing | Register & Pay By Monday, March 24 | On the Door Rate |
|--------------------------|------------------------------------|------------------|
| Conference + 1 Workshop | \$3,498 | \$3,598 |
| Conference Only | \$2,899 | \$2,999 |
| Academic Pricing | Register & Pay By Monday, March 24 | On the Door Rate |
| Conference + 1 Workshop | \$2,998 | \$3,098 |
| Conference Only | \$2,499 | \$2,599 |
| Service Provider Pricing | Register & Pay By Monday, March 24 | On the Door Rate |
| Conference + 1 Workshop | \$4,298 | \$4,398 |
| Conference Only | \$3,599 | \$3,699 |

To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts**

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

**Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue & Accommodation

Hilton Boston Logan Airport

One Hotel Dr, Boston, MA 02128, United States

<https://www.hilton.com/en/hotels/boslhhh-hilton-boston-logan-airport/>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom